Telix Pharmaceuticals (TLX) said over the weekend it filed a biologics license application with the US Food and Drug Administration for TLX250-CDx for the diagnosis and characterization of clear cell renal cell carcinoma, a form of kidney cancer.
The regulator is expected to advise the target action date under the Prescription Drug User Fee Act for the product following a 60-day administrative review process.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。